Literature DB >> 19158472

[A case of pseudomembranous colitis associated with rifampicin therapy in a patient with rectal cancer and gastrointestinal tuberculosis].

Yong Jun Choi1, Hyung Gil Kim, Yun Ah Choi, Woo Chul Joo, Dong Wook Son, Chul Hyun Kim, Yong Woon Shin, Young Soo Kim.   

Abstract

Pseudomembranous colitis (PMC) is known to be associated with the administration of antibiotics which alter normal gastrointestinal flora and allow overgrowth of Clostridium difficile. Most cases of rifampicin-induced PMC are seen in patients with pulmonary tuberculosis, but not with gastrointestinal tuberculosis. We report a case of PMC associated with rifampicin therapy in a patient with gastrointestinal tuberculosis. A 65-year-old female patient with rectal cancer and gastrointestinal tuberculosis was admitted due to abdominal pain and diarrhea. She was treated with anti-tuberculosis agents containing rifampicin. On colonoscopic examination, mucoid exudates and yellowish plaque lesions were observed. Anti-tuberculosis agents were stopped, and the patient was treated with metronidazole. Symptoms were relieved and did not recur when all the anti-tuberculosis agents except rifampicin were started again. When a patient complains of abdominal pain or diarrhea while taking rifampicin, the physician should consider the possibility of rifampicin-associated PMC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158472

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  2 in total

1.  Characterisation of Clostridium difficile strains isolated from Groote Schuur Hospital, Cape Town, South Africa.

Authors:  B Kullin; T Brock; N Rajabally; F Anwar; G Vedantam; S Reid; V Abratt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-27       Impact factor: 3.267

2.  Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland.

Authors:  P Obuch-Woszczatyński; G Dubiel; C Harmanus; E Kuijper; U Duda; D Wultańska; A van Belkum; H Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-27       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.